|
Match
|
Document |
Document Title |
|
|
RE40374 |
Canine IL-13 immunoregulatory proteins and uses thereof
The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon...
|
|
|
7378387 |
Method of suppressing immune response by reducing intracellular content of glutathione in macrophages and monocytes
A method of suppressing immune responses, comprising administering to a patient in need thereof an effective amount of a composition comprising a substance capable of reducing the content of...
|
|
|
7374751 |
QS-21 and IL-12 as an adjuvant combination
Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition...
|
|
|
7371371 |
Interleukin-2 mutants with reduced toxicity
Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular...
|
|
|
7368106 |
Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40...
|
|
|
7361331 |
Plant bioreactors
A plant expressing a cytokine and an autoantigen is disclosed. An example of a cytokine is a contra-inflammatory cytokine, for example IL-4 and IL-10, and an example of autoantigen is GAD. A novel...
|
|
|
7357924 |
Uses of IL-174 for treating helminth infections
Use of the cytokine designated IL-174 to treat infectious diseases such as helminth infections.
|
|
|
7347996 |
Avian cytokines, such as IL-12, comprising a p40 and/or p35 subunit and vaccines
Embodiments of the present invention generally relate to novel avian cytokines, to DNA sequences encoding these novel cytokines and to their use in adjuvants for vaccine purposes.
|
|
|
7347995 |
Compositions and methods for achieving immune suppression
Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.
|
|
|
7335365 |
HIV-encoded chemoattractant
The combination of HIV proteins Tat and Nef is chemotactic for CD4+ cells. Utilizing the capacity of Tat and Nef to modulate CD4+ cell trafficking and infiltration, the invention provides various...
|
|
|
7332156 |
Methods of treating wounds using IL-23
Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods...
|
|
|
7323164 |
Use of interleukin-24 to treat ovarian cancer
The present invention relates to the anti-cancer activity of IL-24 polypeptide molecules. IL-24 is a cytokine involved in inflammatory processes and human disease. The present invention includes...
|
|
|
7311902 |
Conjugates comprising human IL-18 and substitution mutants thereof
Human interleukin-18 (IL-18) polypeptides and substitution mutants thereof were conjugated to water-soluble polymers at specific sites on the human IL-18 protein. These conjugated human IL-18 and...
|
|
|
7306801 |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one...
|
|
|
7285273 |
Method for down-regulating IL5 activity
Improvements in therapy and prevention of conditions characterized by an elevated level of eosinophil leukocytes, i.e. conditions such as asthma and other chronic allergic diseases are disclosed. A...
|
|
|
7279289 |
Method of evaluating myelosuppressive state
The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By...
|
|
|
7279155 |
Method of treatment using a cytokine able to bind IL-18BP to inhibit the activity of a second cytokine
The present invention relates to the use of a cytokine-1, preferably from the IL-1 family more preferably IL-1F7b, or an isoform, mutein, fused protein, functional derivative or fragment thereof,...
|
|
|
7276478 |
Methods of treating autoimmune diseases using IL-21
Administration of IL-21 results in decreasing autoimmune responses and thereby provides a beneficial treatment for autoimmune diseases. Specific autoimmune diseases that may be treated include...
|
|
|
7261894 |
Methods of treating inflammatory and/or autoimmune disease
The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such...
|
|
|
7261882 |
Methods for treating neuropathic pain by administering IL-10 polypeptides
Methods of treating pain by delivery of anti-inflammatory cytokines, proinflammatory cytokine antagonists, and agents that act to reduce or prevent proinflammatory cytokine actions, to the nervous...
|
|
|
7258853 |
Antagonists of interleukin-15
Disclosed herein are mutant IL-15 polypeptides and methods for using these polypeptides to modulate the immune response in a patient.
|
|
|
7232801 |
IL-16 antagonists
In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties...
|
|
|
7220407 |
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
The present invention relates to methods of using Granulocyte Colony Stimulating Factor (G-CSF) polypeptide in conjunction with reperfusion therapy in the treatment of acute myocardial infarction...
|
|
|
7217412 |
IL-17C related mammalian cytokine polypeptides
The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host...
|
|
|
RE39614 |
Canine IL-4 immunoregulatory proteins and uses thereof
The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon...
|
|
|
7208579 |
IL4 receptor antagonists for horse, dog and cat
The present application provides the horse, cat and dog IL4 receptor, including soluble receptors as well as method for therapeutic use of such receptors.
|
|
|
7208149 |
IL-16 antagonist peptides and DNA encoding the peptides
The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The...
|
|
|
7208148 |
Chemically modified cytokines
The invention concerns a derivative of viral regulatory protein or a fragment of viral regulatory protein or of the alpha interferon or a fragment of alpha interferon, which is carboxymethylated, a...
|
|
|
7201896 |
IL6RIL6 chimera for the treatment of neurodegenerative diseases
The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.
|
|
|
7198781 |
Chimeric interleukin-6 soluble receptor/ligand proteins
Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone...
|
|
|
7192578 |
Interleukin-9 mutein peptides
A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1....
|
|
|
7189813 |
PRO1338 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7182942 |
Vaccine immunotherapy for immune suppressed patients
A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of a natural cytokine mixture (NCM), an effective amount of cyclophosphamide...
|
|
|
7164000 |
RANTES mutants and therapeutic applications thereof
RANTES mutants characterised by the substitution or addition of amino acids at the N-terminal of RANTES wild-type sequence and in the N-loop and/or 40's loop regions of RANTES wild-type sequence,...
|
|
|
7160861 |
Methods of inducing IL-10 production
The invention provides a method of inducing IL-10 production.
|
|
|
7160554 |
Enhanced circulation effector composition and method
A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the...
|
|
|
7153499 |
Vaccine immunotherapy for immune suppressed patients
The present invention provides a formulation for inhibiting metastasis which includes 150–600 units of IL-2, a nonsteroidal anti-inflammatory drug (NSAID), and cyclophosphamide. The present...
|
|
|
7150882 |
Enhanced circulation effector composition and method
A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the...
|
|
|
7141434 |
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase
The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds...
|
|
|
7138546 |
Compounds and compositions for delivering active agents
Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
|
|
7138115 |
Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one...
|
|
|
7135181 |
Method for down-regulation of amyloid
A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically...
|
|
|
7135170 |
Methods for treating viral infection using IL-28 and IL-29
IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on...
|
|
|
7128922 |
Compositions of leukaemia inhibitory factor
The present invention relates generally to compositions and more particularly to compositions comprising leukaemia inhibitory factor (hereinafter referred to as “LIF”) or derivative or...
|
|
|
7118737 |
Polymer-modified synthetic proteins
The present invention relates to methods and compositions for modifying peptides, polypeptides and proteins with polymers, especially glyco-mimetic polymers, so as to improve their biological...
|
|
|
7115261 |
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to...
|
|
|
7115259 |
Use of cytokines and mitogens to inhibit pathological immune responses
The invention is generally related to methods of treating autoimmune diseases, including both antibody-mediated and cell-mediated disorders.
|
|
|
7112660 |
Modified cytokine
The invention relates to methods for the stabilisation of cytokines and to cytokines generated by such methods. The methods of the invention involve mutating the amino acid sequence of a cytokine...
|
|
|
7112409 |
Method of determining cytokine dosage for myelosuppressive state
The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By...
|
|
|
7109299 |
Peptides and compounds that bind to the IL-5 receptor
Interleukin-5 receptor (IL-5R) ligands comprising amino sequences of formula TGGGDGYVX 3 VE X 4 ARCPTCK, EGYVX 3 VE X 4 ARCPTCK, EGYVX 3 VE X 4 ARCPTCR, GYVX 3 VE X 4 ARCPTCG, EGYVX 3 VE X 4 ...
|